WO2005054198A3 - Therapeutics use of pyridinium compounds to modulate naadp activity - Google Patents

Therapeutics use of pyridinium compounds to modulate naadp activity Download PDF

Info

Publication number
WO2005054198A3
WO2005054198A3 PCT/GB2004/005109 GB2004005109W WO2005054198A3 WO 2005054198 A3 WO2005054198 A3 WO 2005054198A3 GB 2004005109 W GB2004005109 W GB 2004005109W WO 2005054198 A3 WO2005054198 A3 WO 2005054198A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
pancreatic
modulating
brain
heart
Prior art date
Application number
PCT/GB2004/005109
Other languages
French (fr)
Other versions
WO2005054198A2 (en
Inventor
Barry Victor Lloyd Potter
James Dowden
Antony Galione
Original Assignee
Univ Bath
Barry Victor Lloyd Potter
James Dowden
Antony Galione
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bath, Barry Victor Lloyd Potter, James Dowden, Antony Galione filed Critical Univ Bath
Priority to JP2006542024A priority Critical patent/JP2007516964A/en
Priority to CA002547791A priority patent/CA2547791A1/en
Priority to EP04801265A priority patent/EP1689714A2/en
Priority to AU2004295178A priority patent/AU2004295178A1/en
Publication of WO2005054198A2 publication Critical patent/WO2005054198A2/en
Publication of WO2005054198A3 publication Critical patent/WO2005054198A3/en
Priority to US11/422,010 priority patent/US20070105810A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to the use of a compound of formula (I); wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.
PCT/GB2004/005109 2003-12-05 2004-12-06 Therapeutics use of pyridinium compounds to modulate naadp activity WO2005054198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006542024A JP2007516964A (en) 2003-12-05 2004-12-06 Use of pyridinium compounds as therapeutics to modulate NAADP activity
CA002547791A CA2547791A1 (en) 2003-12-05 2004-12-06 Therapeutics use of pyridinium compounds to modulate naadp activity
EP04801265A EP1689714A2 (en) 2003-12-05 2004-12-06 Therapeutic use of pyridinium compounds to modulate naadp activity
AU2004295178A AU2004295178A1 (en) 2003-12-05 2004-12-06 Therapeutics use of pyridinium compounds to modulate NAADP activity
US11/422,010 US20070105810A1 (en) 2003-12-05 2006-06-02 Therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328314.0A GB0328314D0 (en) 2003-12-05 2003-12-05 Therapeutics
GB0328314.0 2003-12-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/422,010 Continuation-In-Part US20070105810A1 (en) 2003-12-05 2006-06-02 Therapeutics

Publications (2)

Publication Number Publication Date
WO2005054198A2 WO2005054198A2 (en) 2005-06-16
WO2005054198A3 true WO2005054198A3 (en) 2005-09-15

Family

ID=29764706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/005109 WO2005054198A2 (en) 2003-12-05 2004-12-06 Therapeutics use of pyridinium compounds to modulate naadp activity

Country Status (6)

Country Link
EP (1) EP1689714A2 (en)
JP (1) JP2007516964A (en)
AU (1) AU2004295178A1 (en)
CA (1) CA2547791A1 (en)
GB (1) GB0328314D0 (en)
WO (1) WO2005054198A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132179A2 (en) * 2006-05-15 2007-11-22 University Of Bath Therapeutics comprising pyridinium derivatives
CN102491944A (en) * 2011-12-13 2012-06-13 东阳市威达环保助剂有限公司 Method for preparing brominated 1-benzyl-3-carboxypyridine and preparation method thereof
JP2023509947A (en) * 2020-01-10 2023-03-10 オーフス ウニベルシテット A compound for promoting follicular maturation
CN113277977B (en) * 2021-05-25 2022-10-04 德锡化学(山东)有限公司 Trigonelline compound and synthesis method and application thereof
TW202404581A (en) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044925A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
WO1998057662A2 (en) * 1997-06-14 1998-12-23 Enzacta R & D Limited Therapeutic systems
WO1999036422A1 (en) * 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
WO1999043754A1 (en) * 1998-02-28 1999-09-02 Avecia Limited Monoazo dyestuffs, a composition and an ink for ink jet printing comprising them
WO2001025209A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
WO2002011736A1 (en) * 2000-08-04 2002-02-14 University Of Bath Naadp analogues for modulating t-cell activity
EP1304101A1 (en) * 2001-10-19 2003-04-23 Torrent Pharmaceuticals Ltd Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
WO2003089459A2 (en) * 2002-04-19 2003-10-30 University Of Florida Thyrotropin-releasing hormone analogues and their therapeutic applications

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044925A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
WO1998057662A2 (en) * 1997-06-14 1998-12-23 Enzacta R & D Limited Therapeutic systems
WO1999036422A1 (en) * 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
WO1999043754A1 (en) * 1998-02-28 1999-09-02 Avecia Limited Monoazo dyestuffs, a composition and an ink for ink jet printing comprising them
WO2001025209A1 (en) * 1999-10-06 2001-04-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications
WO2002011736A1 (en) * 2000-08-04 2002-02-14 University Of Bath Naadp analogues for modulating t-cell activity
EP1304101A1 (en) * 2001-10-19 2003-04-23 Torrent Pharmaceuticals Ltd Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
WO2003089459A2 (en) * 2002-04-19 2003-10-30 University Of Florida Thyrotropin-releasing hormone analogues and their therapeutic applications

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BECHARA, E. J. H. ET AL: "Formation of adenosine triphosphate in the oxidation of a model for the reduced pyridine nucleotides", BIOCHEMISTRY , 11(14), 2606-10 CODEN: BICHAW; ISSN: 0006-2960, 1972, XP008044841 *
BODOR, NICHOLAS ET AL: "Improved delivery through biological membranes. XIX: Novel redox carriers for brain-specific chemical delivery systems", JOURNAL OF PHARMACEUTICAL SCIENCES , 74(3), 241-5 CODEN: JPMSAE; ISSN: 0022-3549, 1985, XP008044866 *
BREWSTER, MARCUS E. ET AL: "The effect of dihydronicotinate N-substitution on the brain-targeting efficacy of a zidovudine chemical delivery system", PHARMACEUTICAL RESEARCH , 10(9), 1356-62 CODEN: PHREEB; ISSN: 0724-8741, 1993, XP000789917 *
FARAG, HASSAN H. ET AL: "Synthesis and preliminary alkylating activities of certain new 1,4-dihydropyridines, pyridinium salts and 2,7-diazabicyclo[4.1.0]hept-3- enes", BULLETIN OF PHARMACEUTICAL SCIENCES, ASSIUT UNIVERSITY , 16(2), 141-50 CODEN: BPAUEC; ISSN: 1110-0052, 1993, XP008044846 *
POP, EMIL ET AL: "Novel redox derivatives of tryptophan", HETEROCYCLES , 38(9), 2051-64 CODEN: HTCYAM; ISSN: 0385-5414, 1994, XP008044865 *
TOMIZAKI, KIN-YA ET AL: "Design and characterization of flavoenzyme models in the course of chemical evolution of four-.alpha.-helix bundle polypeptides", PERKIN 2 , (4), 813-822 CODEN: PRKTFO, 2000, XP008044843 *
VAN ESCH, J. H. ET AL: "Reduction of Nicotinamides, Flavins, and Manganese Porphyrins by Formate, Catalyzed by Membrane-Bound Rhodium Complexes", JOURNAL OF ORGANIC CHEMISTRY , 60(6), 1599-610 CODEN: JOCEAH; ISSN: 0022-3263, 1995, XP008044842 *
ZHU, XIAO-QING ET AL: "Thermodynamics and kinetics of the hydride-transfer cycles for 1-aryl-1,4-dihydronicotinamide and its 1,2-dihydroisomer", CHEMISTRY--A EUROPEAN JOURNAL , 9(16), 3937-3945 CODEN: CEUJED; ISSN: 0947-6539, 2003, XP008044844 *

Also Published As

Publication number Publication date
JP2007516964A (en) 2007-06-28
WO2005054198A2 (en) 2005-06-16
EP1689714A2 (en) 2006-08-16
CA2547791A1 (en) 2005-06-16
GB0328314D0 (en) 2004-01-07
AU2004295178A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
EP1828167B1 (en) Acrylamide derivatives as antibiotic agents
CN105051041B (en) Heterocycle glutamine enzyme inhibitor
KR102642823B1 (en) Compositions and methods for controlling hair growth
BR9916590A (en) Pyrimidine derivative, process for preparing a pyrimidine derivative, method for producing an anti-cancer effect in a warm-blooded animal, use of the pyrimidine derivative, and pharmaceutical composition
US5002961A (en) Method for reducing injury with imidazol-2-thionecarboxamides
NO822974L (en) URINARY DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM AND THEIR USE
UA116992C2 (en) Treatment of immune-related and inflammatory diseases
PL167682B1 (en) Method of obtaining nucleoside analogs of 1,3-oxathiolane
JP2002533347A (en) Fused 1,2,4-thiadiazine derivatives, their production and use
US6017925A (en) Integrin antagonists
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
BG60306B2 (en) Method for the preparation of substituted twin-ring compounds
EP1594885B8 (en) Medicament for inhibiting tumour growth
EA026686B1 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)pyridin-2-yl]-1h-pyrazol-3-yl} ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
EP0842178A1 (en) Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
WO2005054198A3 (en) Therapeutics use of pyridinium compounds to modulate naadp activity
WO2007132179A3 (en) Therapeutics comprising pyridinium derivatives
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
MX2020013847A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof.
RS20050231A (en) Pyrrole derivatives as antimycobacterial compounds
BR0317433A (en) Bicyclic Derivatives for the Treatment of Abnormal Cell Growth
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
TW201544108A (en) Use of an isoquinoline alkaloid derivative in manufacturing a medication effective in AMPK activation
EP2903969A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
PE20040916A1 (en) PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004295178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2547791

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 547613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 11422010

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006542024

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004295178

Country of ref document: AU

Date of ref document: 20041206

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004295178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004801265

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004801265

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11422010

Country of ref document: US